Serum Thyroglobulin Assays Compared for Differentiated Thyroid Carcinoma
By LabMedica International staff writers Posted on 05 Oct 2020 |
Image: LIAISON XL is a fully automated chemiluminescence analyzer, performing complete sample processing as well as measurement and evaluation (Photo courtesy of Diasorin).
Measurement of serum thyroglobulin (Tg) plays a key role in the post‐thyroidectomy management of differentiated thyroid carcinoma (DTC). In this context, the performance of new‐generation thyroglobulin assay has clinical implications in the follow‐up of DTC patients.
Following total thyroidectomy, serum Tg levels are expected to be undetectable. On this basis, postoperative circulating Tg levels are used as a tumor marker to assess completely surgical resection and recurrence in the follow‐up of well‐differentiated thyroid cancer (DTC). The addition of Tg concentration of fine‐needle washouts (FNA‐Tg) of the suspicious lymph node to fine‐needle aspiration cytology (FNAC) showed improved prediction of lymph node metastases (LNM).
Medical Scientists at the University of Naples “Federico II” (Naples, Italy) selected a total of 91 residual serum samples between September 2019 and December 2019. These subjects comprised 35 men and 56 women, and their mean age was 48.2 ± 17.0 years. Serum postsurgical Tg lower than 1‐2 ng/mL is a strong predictor of remission, whereas Tg levels more than 10‐30 ng/mL are associated with persistent or recurrent disease. Study samples were from 21 patients with pathologically proven DTC and control samples from 70 (16 patients with benign thyroid disease and 54 apparently healthy subjects).
Tg was determined by using two different chemiluminescence immunoassays (CLIA). Specifically, these included Liaison (Tg-L, Liaison XL, Diasorin, Saluggia, Italy) and Beckman UniCeL DxI800 (Tg-A, Access, Beckman Coulter Inc, Brea, CA, USA). Thyroglobulin antibodies (TgAbs) were determined by Siemens ADVIA Centaur (Siemens Healthcare Diagnostics Products Ltd., Llanberis, UK).
The investigators reported that the results showed that Tg‐L was highly correlated with Tg‐A for both values ranging between 0.2 and 50 ng/mL) and higher than 50 ng/mL. For Tg values lower than 0.2 ng/mL, the overall concordance rate was 92%. Moreover, they tested seven fine‐needle aspiration washout fluids (FNA), showing an overall concordance rate in discriminating negative and positive of 100%. Finally, they found no interference by Tg auto‐antibodies (TgAbs) for both Tg‐L and Tg‐A. Conversely, rheumatoid factor (RF) interferes with Tg‐A, but not with Tg‐L in one patient with no relapsing thyroid carcinoma.
The authors concluded that preliminary data on a small study population suggests a good correlation between Liaison Tg II assay and the well‐established Access immunoassay. Further studies on larger population are needed to confirm the findings and to evaluate the clinical performance of this new immunoassay in the follow‐up of DTC patients. The study was published on September 20, 2020 in the Journal of Clinical Laboratory Analysis.
Following total thyroidectomy, serum Tg levels are expected to be undetectable. On this basis, postoperative circulating Tg levels are used as a tumor marker to assess completely surgical resection and recurrence in the follow‐up of well‐differentiated thyroid cancer (DTC). The addition of Tg concentration of fine‐needle washouts (FNA‐Tg) of the suspicious lymph node to fine‐needle aspiration cytology (FNAC) showed improved prediction of lymph node metastases (LNM).
Medical Scientists at the University of Naples “Federico II” (Naples, Italy) selected a total of 91 residual serum samples between September 2019 and December 2019. These subjects comprised 35 men and 56 women, and their mean age was 48.2 ± 17.0 years. Serum postsurgical Tg lower than 1‐2 ng/mL is a strong predictor of remission, whereas Tg levels more than 10‐30 ng/mL are associated with persistent or recurrent disease. Study samples were from 21 patients with pathologically proven DTC and control samples from 70 (16 patients with benign thyroid disease and 54 apparently healthy subjects).
Tg was determined by using two different chemiluminescence immunoassays (CLIA). Specifically, these included Liaison (Tg-L, Liaison XL, Diasorin, Saluggia, Italy) and Beckman UniCeL DxI800 (Tg-A, Access, Beckman Coulter Inc, Brea, CA, USA). Thyroglobulin antibodies (TgAbs) were determined by Siemens ADVIA Centaur (Siemens Healthcare Diagnostics Products Ltd., Llanberis, UK).
The investigators reported that the results showed that Tg‐L was highly correlated with Tg‐A for both values ranging between 0.2 and 50 ng/mL) and higher than 50 ng/mL. For Tg values lower than 0.2 ng/mL, the overall concordance rate was 92%. Moreover, they tested seven fine‐needle aspiration washout fluids (FNA), showing an overall concordance rate in discriminating negative and positive of 100%. Finally, they found no interference by Tg auto‐antibodies (TgAbs) for both Tg‐L and Tg‐A. Conversely, rheumatoid factor (RF) interferes with Tg‐A, but not with Tg‐L in one patient with no relapsing thyroid carcinoma.
The authors concluded that preliminary data on a small study population suggests a good correlation between Liaison Tg II assay and the well‐established Access immunoassay. Further studies on larger population are needed to confirm the findings and to evaluate the clinical performance of this new immunoassay in the follow‐up of DTC patients. The study was published on September 20, 2020 in the Journal of Clinical Laboratory Analysis.
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes